# Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)

> **NCT03777085** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 230 (estimated)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** TQB2303
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03777085
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-10
- **Primary completion:** 2020-12-30
- **Final completion:** 2020-12-30
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2019-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03777085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03777085, "Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03777085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*